Application of FBXO40 in preparation of medicine for treating myocardial fibrosis and cervical cancer after ischemia triggered by overexpression of SOX9 protein

By using FBXO40 to inhibit ubiquitination modification of SOX9 protein, drugs for the treatment of post-ischemia myocardial fibrosis and cervical cancer caused by overexpression of SOX9 protein are developed, solving the problem of lack of effective targeting SOX9 protein inhibitors in the prior art. , effective treatment and prognosis evaluation of myocardial fibrosis and cervical cancer have been achieved.

CN118873641APending Publication Date: 2024-11-01THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410963086.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The lack of small molecule inhibitors or compounds that directly target SOX9 proteins makes it difficult to effectively treat diseases related to SOX9 protein overexpression that cause post-ischemia myocardial fibrosis and cervical cancer.

Method used

Using FBXO40 or its homologous protein sequence, drugs for the treatment of post-ischemia myocardial fibrosis and cervical cancer caused by overexpression of SOX9 protein are developed. .

Benefits of technology

Exogenously specific overexpression of FBXO40 can effectively inhibit the occurrence and development of cardiac fibrosis and cervical cancer caused by ischemia and reperfusion injury, and the difference in FBXO40 expression can be used as a pathological diagnostic indicator for the prognosis of cervical cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118873641A_ABST
    Figure CN118873641A_ABST
Patent Text Reader

Abstract

The invention discloses an application of FBXO40 in preparation of a medicine for treating myocardial fibrosis and cervical cancer after ischemia triggered by overexpression of SOX9 protein. On the basis that a K2 protein structural domain is a main region of SOX9 protein ubiquitination modification, a deubiquitination enzyme capable of inhibiting SOX9 protein ubiquitination degradation in an F-box family is screened, and screening finds that the deubiquitination enzyme FBXO40 can inhibit SOX9 protein homeostasis; functional experiments find that exogenous specific overexpression FBXO40 can restrain cardiac fibrosis caused by ischemia-reperfusion injury and the occurrence and development of cervical cancer. In addition, a cervical cancer clinical pathological tissue specimen is collected and subjected to immunohistochemical detection, and it is found that the expression intensity difference of FBXO40 can be used as a pathological diagnosis index for evaluating prognosis of a clinical cervical cancer patient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of single-target multi-purpose (cardiovascular disease and tumor) gene therapy research, and provides the use of FBXO40 in the preparation of a drug for treating post-ischemic myocardial fibrosis and cervical cancer triggered by overexpression of SOX9 protein. Background Art

[0002] Cardiovascular disease (CVD) and cancer are the leading causes of morbidity and mortality worldwide. Recognition and understanding of common risk factors for ischemic injury-induced cardiac fibrosis and cancer are important to deepen our understanding of the shared genetic and molecular mechanisms underlying the pathogenesis of both diseases. Accumulating evidence suggests that ischemic injury-induced cardiac fibrosis and cancer share similarities in their pathogenesis, including protein post-translational modification remodeling, proliferation, and fibroblast activation. Therefore, understanding the important shared molecular and genetic pathways between CVD and cancer is crucial and may help develop new therapeutic and preventive strategies.

[0003] SOX9 is a transcription factor that regulates various biological functions and pathological processes, including tumor progression, regeneration, ischemia / reperfusion injury (IRI), fibrosis, and cell survival, and is therefore a potential therapeutic target. Studies have shown that SOX9 is abnormally highly expressed in a variety of tumors (including cervical cancer) and plays an important oncogene function in promoting tumor progression. In the mouse cardiac ischemia / reperfusion injury model and the corresponding human tissue specimens, the detection of cardiac tissue detection found that SOX9 was abnormally highly expressed and promoted cardiac fibrosis, suggesting that targeting SOX9 can be used as a potential target for the treatment of cardiac ischemia / reperfusion injury-mediated fibrosis. However, there is currently a lack of small molecule inhibitors or compounds that directly target the SOX9 protein. Therefore, the development or screening of inhibitors / drugs targeting the SOX9 protein may achieve a "one stone, two birds" therapeutic effect, which has a certain urgency and important clinical translation application value. Summary of the invention

[0004] In view of this, the object of the present invention is to provide the use of FBXO40 in the preparation of a drug for treating post-ischemic myocardial fibrosis and cervical cancer triggered by overexpression of SOX9 protein.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] 1. Use of FBXO40 or an agent overexpressing FBXO40 in the preparation of a drug for inhibiting SOX9 protein homeostasis or promoting SOX9 protein degradation, wherein FBXO40 has any one of the following sequences:

[0007] (1) the amino acid sequence shown in SEQ ID NO.1;

[0008] (2) An amino acid sequence obtained by replacing, deleting and / or adding one or more amino acid sequences of the amino acid sequence of (1), and a homologous protein sequence having the same function as the amino acid sequence of (1).

[0009] 2. Use of FBXO40 or an agent overexpressing FBXO40 in the preparation of a drug for treating myocardial fibrosis after ischemia triggered by overexpression of SOX9 protein, wherein FBXO40 has any one of the following sequences:

[0010] (1) the amino acid sequence shown in SEQ ID NO.1;

[0011] (2) An amino acid sequence obtained by replacing, deleting and / or adding one or more amino acid sequences of the amino acid sequence of (1), and a homologous protein sequence having the same function as the amino acid sequence of (1).

[0012] 3. Use of FBXO40 or an agent overexpressing FBXO40 in the preparation of a drug for treating cervical cancer triggered by overexpression of SOX9 protein, wherein FBXO40 has any one of the following sequences:

[0013] (1) the amino acid sequence shown in SEQ ID NO.1;

[0014] (2) An amino acid sequence obtained by replacing, deleting and / or adding one or more amino acid sequences of the amino acid sequence of (1), and a homologous protein sequence having the same function as the amino acid sequence of (1).

[0015] 4. Use of a reagent for detecting the expression of FBXO40 in the preparation of a cervical cancer prognosis detection kit, wherein FBXO40 has any one of the following sequences:

[0016] (1) the amino acid sequence shown in SEQ ID NO.1;

[0017] (2) An amino acid sequence obtained by replacing, deleting and / or adding one or more amino acid sequences of the amino acid sequence of (1), and a homologous protein sequence having the same function as the amino acid sequence of (1).

[0018] The beneficial effects of the present invention are:

[0019] Based on the fact that the K2 protein domain is the main region of SOX9 protein ubiquitination modification, the present invention screened the F-box family of deubiquitinases that can inhibit the ubiquitination degradation of SOX9 protein, and found that the deubiquitinase FBXO40 can inhibit the homeostasis of SOX9 protein; functional experiments found that exogenous specific overexpression of FBXO40 can inhibit the occurrence and development of cardiac fibrosis and cervical cancer caused by ischemia-reperfusion injury. In addition, clinical pathological tissue specimens of cervical cancer were collected and tested by immunohistochemistry, and it was found that the difference in the expression of FBXO40 can be used as a pathological diagnostic indicator to evaluate the prognosis of clinical cervical cancer patients.

[0020] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:

[0022] Figure 1 To screen for new E3 ubiquitin ligases that regulate SOX9 protein expression based on F-Box family proteins; wherein, A is HEK293T cells exogenously overexpressing HA-tagged F-Box and Flag-tagged SOX9, and the expression of SOX9 protein was detected by protein immunoblotting; B is F-Box protein molecules that form protein complexes with SOX9 screened by Co-IP detection.

[0023] Figure 2 FBXO40 inhibits SOX9 protein homeostasis; A is the effect of protein immunoprecipitation and immunoblotting analysis on the ubiquitination modification level of SOX9 protein by knocking out FBXO40; B is the change of SOX9 protein half-life detected by actinomycin and immunoblotting in cardiomyocytes AC16 after knocking out FBXO40; C is the immunoblotting analysis of SOX9 protein level under different culture conditions of hypoxia and hypoxia-reoxygenation after knocking out FBXO40 in cardiomyocytes AC16.

[0024] Figure 3The myocardial-specific overexpression of Fbxo40 in rats does not affect normal cardiac function; A is a representative ultrasound image of rat hearts in different groups; B is the statistical analysis results of ejection fraction and left ventricular short-axis shortening rate after ultrasound of rat hearts in different groups; C is a representative statistical analysis of serological detection indicators in rats in different groups; D is a representative HE staining result of rat heart tissue in different groups; E is the Masson staining result of rat heart tissue in different groups.

[0025] Figure 4 The myocardial-specific overexpression of Fbxo40 in rats reduces the level of fibrosis caused by ischemia-reperfusion injury; A is a representative ultrasound image of the rat hearts of different groups, and a statistical analysis of the ratio of heart weight to body weight; B is a representative ultrasound image of the rat hearts of different groups, and the statistical analysis results of indicators such as ejection fraction and left ventricular short-axis shortening; C is a representative statistical analysis of serological detection indicators of rats in different groups; D is the HE staining result of rat heart tissue in different groups; E is a representative Masson staining of rat heart tissue in different groups and statistical analysis of the results; F is the expression of collagen III in the infarcted area of ​​the heart of different groups of rats detected by immunohistochemistry; G is a representative Sirius red staining and polarized light detection of rat heart fibrosis changes in different groups and statistical analysis of the results; H and I are representative immunohistochemical detection of α-SMA and POSTN expression changes in rat heart tissue in different groups.

[0026] Figure 5 The relationship between FBXO40 expression in pan-cancer and survival prognosis was analyzed based on the TCGA database; A is the distribution of FBXO40 gene change frequency in various cancer types; B is the overall survival prognosis analysis of FBXO40 expression in different cancer patients; C is the prognostic analysis of the overall survival and disease-free survival of cervical cancer patients with FBXO40 expression; D is the prognostic analysis of the overall survival and disease-free survival of cervical cancer patients with SOX9 expression.

[0027] Figure 6 Overexpression of FBXO40 in cervical cancer cells can significantly inhibit the proliferation and tumor formation ability of cervical cancer; A is the cell proliferation (CCK-8) detection experiment found that overexpression of FBXO40 in cervical cancer cells can significantly inhibit the proliferation ability; B is overexpression of FBXO40 in cervical cancer cells can significantly inhibit the clone formation ability; C and D are overexpression of FBXO40 in cervical cancer cells can significantly inhibit the subcutaneous transplant tumor formation ability.

[0028] Figure 7The difference in FBXO40 expression can be used as a clinical pathological detection indicator for the prognosis of cervical cancer; A is the immunohistochemical method to detect the protein expression and correlation of FBXO40 and SOX9 in liver cancer tissue; B and C are Kaplan-Meier survival curves to analyze the relationship between the difference in FBXO40 and SOX9 expression and the prognosis of cervical cancer. DETAILED DESCRIPTION

[0029] The present invention will be further described below in conjunction with specific implementation modes.

[0030] The cardiomyocytes AC16 and cervical cancer cell line Hela cells used in the present invention were purchased from the cell bank of the Chinese Academy of Sciences; the cell transfection kit was purchased from QIAGEN Company of the United States.

[0031] EnvisionTM and DAB colorimetric solution used in the present invention were purchased from DAKO, Denmark; EDTA (pH 8.0) antigen retrieval solution was purchased from Fuzhou Maixin Biotechnology Development Co., Ltd. AAV9-cTnT-Control and AAV9-cTnT-FBXO40 adeno-associated viruses and Lv-FBXO40 and shFBXO40 lentiviruses were purchased from Shanghai Jikai Biotechnology Co., Ltd.

[0032] Screening of E3 ubiquitin ligase FBXO40 targeting SOX9

[0033] Depend on Figure 1 As shown in A and B, FBXO40 and SOX9 form a protein complex and specifically reduce SOX9 expression. At the same time, during the F-Box family screening process, we also overexpressed the reported KEAP1 and FBXW7 (which can promote the ubiquitination degradation of SOX9 protein and inhibit its expression) as positive controls. Protein immunoblotting and protein immunoprecipitation methods confirmed that KEAP1 and FBXW7 can also form a complex with SOX9 protein and inhibit its expression under the applicant's research system, indicating that the applicant's screening research system is authentic and reliable.

[0034] Depend on Figure 5 As shown in A to D, the pan-cancer analysis of the TCGA database shows that the expression of FBXO40 is only correlated with prognosis in cervical cancer (high expression indicates a good prognosis, low expression indicates a poor prognosis), but not in other cancers; and strong expression of SOX9 indicates a poor prognosis in cervical cancer, while weak expression indicates a good prognosis.

[0035] Example 1

[0036] Previous studies have shown that the ubiquitin-protein degradation system plays a key role in regulating the ubiquitination modification of SOX9 protein and inhibiting its expression. In order to systematically explore and screen out the key F-Box protein molecules that regulate SOX9 expression, the applicant constructed an overexpression plasmid screening system for the F-Box family and found that FBXO40 and SOX9 form a protein complex and specifically reduce SOX9 expression ( Figure 1 A and B); At the same time, during the F-Box family screening process, we also overexpressed the reported KEAP1 and FBXW7 (which can promote the ubiquitination degradation of SOX9 protein and inhibit its expression) as positive controls. Protein immunoblotting and protein immunoprecipitation methods confirmed that KEAP1 and FBXW7 can also form a complex with SOX9 protein and inhibit its expression in the applicant's research system ( Figure 1 A and B), indicating that the applicant's screening research system is authentic and reliable.

[0037] Example 2

[0038] Targeted inhibition of FBXO40 promotes SOX9 protein homeostasis

[0039] Previous studies have found that SOX9 can be used as a detection index for cardiac fibrosis and tumors, suggesting that the development or screening of inhibitors / drugs targeting SOX9 can enhance the therapeutic efficacy of related diseases (cardiovascular diseases and tumors), but there is currently a lack of inhibitory measures. In order to screen out the molecules / inhibitors that regulate the homeostasis of SOX9 protein, the applicant screened the F-box library and found that FBXO40 negatively regulates the ubiquitination modification of SOX9 protein ( Figure 2 A), and found that knocking out FBXO40 can prolong the half-life of SOX9 protein ( Figure 2 Middle B); After knocking out FBXO40 in AC16 cardiomyocytes, under different culture conditions of hypoxia and hypoxia-reoxygenation (in vitro simulating ischemia-reperfusion injury model), the expression level of SOX9 increased under the conditions of knocking out FBXO40 and hypoxia-reoxygenation culture ( Figure 2 The above results suggest that targeted promotion of FBXO40 expression can serve as a key molecule for degrading SOX9 protein.

[0040] Example 3

[0041] Myocardial-specific overexpression of Fbxo40 does not affect normal cardiac function in rats

[0042] Previous studies have shown that cardiac ischemia-reperfusion injury enhances SOX9 expression and promotes the occurrence of fibrosis, and adeno-associated virus is currently a clinically effective gene delivery system and method for treating diseases. Based on the fact that FBXO40 can inhibit SOX9 protein expression, the applicant hypothesizes that targeting FBXO40 may be able to treat or improve the formation of cardiac fibrosis mediated by ischemia-reperfusion injury. It is worth noting that rats were injected with adeno-associated viruses that specifically express Fbxo40 in the myocardium through the tail vein. Four weeks later, cardiac ultrasound and serological tests showed that overexpression of Fbxo40 did not change the biological function of the heart compared with the control group ( Figure 3 In addition, by taking the heart tissues of rats in different groups and performing HE staining and Masson staining, it was found that the heart tissue structure did not change ( Figure 3 (D and E), the above results indicate that using adeno-associated virus to deliver FBXO40 to cardiomyocytes for its specific high expression is a safe and reliable method.

[0043] Example 4

[0044] Myocardial-specific overexpression of Fbxo40 reduces ischemia-reperfusion injury-induced cardiac fibrosis in rats

[0045] In order to further explore the effect of targeting FBXO40 on myocardial fibrosis caused by ischemia-reperfusion injury. The applicant first established a rat cardiac ischemia-reperfusion model. Ten days after modeling, the exogenous overexpression of Fbxo40 significantly improved the effect of ischemia-reperfusion injury on cardiac function compared with the control group through cardiac ultrasound and serological tests ( Figure 4 A, B, and C); HE staining and Masson staining were performed on the heart tissues of rats in different groups. It was found that overexpression of FBXO40 could significantly reduce the area of ​​fibrosis caused by ischemia-reperfusion injury ( Figure 4 In addition, the protective effect of Fbxo40 on the heart during ischemia-reperfusion injury was further confirmed by collagen type III immunohistochemistry, picrosirius red staining and polarized light detection ( Figure 4 At the same time, immunohistochemistry was used to detect the expression of fibroblast expression indicators - α-SMA and POSTN, and it was found that overexpression of Fbxo40 could significantly reduce the expression levels of α-SMA and POSTN ( Figure 4 The above in vivo functional test results show that targeting FBXO40 can significantly reduce the effect of ischemia-reperfusion injury on cardiac fibrosis and plays an important role in protecting and maintaining the normal biological function of the heart.

[0046] Example 5

[0047] Studies have found that SOX9 is abnormally highly expressed in a variety of tumor tissues, and its high expression is closely related to poor clinical prognosis. Based on the negative regulation of SOX9 protein expression by FBXO40, the applicant found that FBXO40 has different expression differences in a variety of tumors based on the analysis of the TCGA database ( Figure 5 Middle A); Through the analysis of FBXO40 expression and pan-cancer survival prognosis, it was found that FBXO40 expression was only correlated with prognosis in cervical cancer (high expression had a good prognosis, low expression had a poor prognosis), but not in other cancers ( Figure 5 B and C); strong SOX9 expression in cervical cancer indicates poor prognosis, while weak expression indicates good prognosis ( Figure 5 (middle D).

[0048] Example 6

[0049] Overexpression of FBXO40 in cervical cancer cells can significantly inhibit the proliferation and tumor formation of cervical cancer

[0050] Previous studies have shown that SOX9 is closely related to tumor formation and is abnormally highly expressed in a variety of tumor models. Based on the applicant's previous research results, the applicant continued to explore whether targeting FBXO40 can inhibit the occurrence and development of cervical cancer. Based on this, the applicant exogenously overexpressed FBXO40 in cervical cancer cells and found through in vitro cell biological function detection that compared with the control group, overexpression of FBXO40 can significantly reduce the proliferation and cloning ability of cervical cancer ( Figure 6 In vivo biological function detection in mice found that overexpression of FBXO40 could significantly delay the growth of subcutaneous transplanted tumors in mice compared with the control group ( Figure 6 (C, D) The above in vivo and in vitro functional test results show that targeting FBXO40 can inhibit the cloning and tumor proliferation of cervical cancer cells and has a strong ability to delay tumor cell proliferation.

[0051] Example 7

[0052] Differential expression of FBXO40 can be used as a clinical pathological indicator for the prognosis of cervical cancer

[0053] The applicant studied the relationship between FBXO40 expression and clinical prognosis in cervical cancer patients. In order to directly evaluate the relationship between FBXO40 expression and prognosis in cancer patients, the applicant performed immunohistochemical staining on 111 paraffin-embedded tissue specimens. According to the statistical results of FBXO40 and SOX9 immunohistochemical staining, the cancer patients were divided into two groups, namely the high expression group and the low expression group. The expression of the two groups was negatively correlated ( Figure 7Compared with patients with low FBXO40 expression, patients with high FBXO40 expression had better survival prognosis; and compared with patients with high SOX9 expression, patients with low SOX9 expression had better prognosis ( Figure 7 These data from cancer patients support the clinical relevance of the applicant's experimental results in the FBXO40-targeted mouse tumor model ( Figure 6 Together, these findings highlight the potential clinical translational application of targeting FBXO40 as a therapeutic approach to treat or ameliorate cardiac ischemia-reperfusion injury-mediated fibrosis and cervical cancer.

[0054] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.

Claims

1. Use of FBXO40 or an agent overexpressing FBXO40 in the preparation of a drug for inhibiting SOX9 protein homeostasis or promoting SOX9 protein degradation, characterized in that: FBXO40 has any of the following sequences: (1) the amino acid sequence shown in SEQ ID NO.1; (2) An amino acid sequence obtained by replacing, deleting and / or adding one or more amino acid sequences of the amino acid sequence of (1), and a homologous protein sequence having the same function as the amino acid sequence of (1).

2. Use of FBXO40 or an agent overexpressing FBXO40 in the preparation of a drug for treating post-ischemic myocardial fibrosis triggered by overexpression of SOX9 protein, characterized in that: Any of the following sequences: (1) the amino acid sequence shown in SEQ ID NO.1; (2) An amino acid sequence obtained by replacing, deleting and / or adding one or more amino acid sequences of the amino acid sequence of (1), and a homologous protein sequence having the same function as the amino acid sequence of (1).

3. Use of FBXO40 or an agent overexpressing FBXO40 in the preparation of a drug for treating cervical cancer triggered by overexpression of SOX9 protein, characterized in that: FBXO40 has any of the following sequences: (1) the amino acid sequence shown in SEQ ID NO.1; (2) An amino acid sequence obtained by replacing, deleting and / or adding one or more amino acid sequences of the amino acid sequence of (1), and a homologous protein sequence having the same function as the amino acid sequence of (1).

4. Use of a reagent for detecting the expression of FBXO40 in preparing a cervical cancer prognosis detection kit, characterized in that: FBXO40 has any of the following sequences: (1) the amino acid sequence shown in SEQ ID NO.1; (2) An amino acid sequence obtained by replacing, deleting and / or adding one or more amino acid sequences of the amino acid sequence of (1), and a homologous protein sequence having the same function as the amino acid sequence of (1).